{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:30:28Z","timestamp":1786113028005,"version":"build-2736575974"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>This meta-analysis aimed to systematically evaluate the efficacy and safety of denosumab versus conventional medications in treating osteoporosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Randomized controlled trials from PubMed, ScienceDirect, Web of Science, CNKI, WanFang Data, and VIP were searched via the web from the onset to April 2025. RevMan 5.4 software was used for performing a systematic review. Trial sequential analysis (TSA) of serious adverse events (SAEs) was performed using TSA 0.9.5.10 Beta.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 15 studies with 16,437 patients were included. Compared to the control group (conventional medications), the experimental group with denosumab showed no significant difference in increasing total hip bone mineral density (BMD) (mean difference [MD]\u2005=\u20050.03, 95% confidence interval [CI]\u2005=\u2005[0.00\u20130.06],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.06) and femoral neck BMD (MD\u2005=\u20050.02, 95% CI\u2005=\u2005[\u22120.04 to 0.08],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.43), but it significantly improved lumbar spine BMD (MD\u2005=\u20050.07, 95% CI\u2005=\u2005[0.03\u20130.11],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.003). In addition, there were no differences between the 2 groups in terms of reducing osteonecrosis of the jaw (odds ratio [OR]\u2005=\u20051.49, 95% CI\u2005=\u2005[0.65\u20133.46],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.35), atypical fractures (OR\u2005=\u20051.77, 95% CI\u2005=\u2005[0.38\u20138.31],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.47), AEs (OR\u2005=\u20050.98, 95% CI\u2005=\u2005[0.91\u20131.07],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.71), and SAEs (OR\u2005=\u20050.94, 95% CI\u2005=\u2005[0.53\u20131.69],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.85), and TSA showed an insufficient information size with SAEs of denosumab compared with conventional medications in the treatment of osteoporosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>It can be concluded that denosumab can improve lumbar spine BMD compared with conventional medications for osteoporosis; furthermore, no evidence was found that the denosumab had a significantly higher incidence of SAEs than the control group and it is safe to apply. However, given the potential bias of the included studies, more high-quality, large-sample randomized controlled trials are needed to validate this conclusion further and to provide a more reliable basis for the use of medication in the clinical treatment of osteoporosis. The registration number in PROSPERO is CRD420251051061 (http:\/\/www.crd.york.ac.uk\/PROSPERO\/).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000047150","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:01:55Z","timestamp":1767988915000},"page":"e47150","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of denosumab compared with conventional medications in the treatment of osteoporosis: A meta-analysis with trial sequential analysis"],"prefix":"10.1097","volume":"105","author":[{"given":"Liang","family":"Li","sequence":"first","affiliation":[{"name":"Department of Orthopedics, Affiliated Hospital 6 of Nantong University, Yancheng 224001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Affiliated Hospital 6 of Nantong University, Yancheng 224001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7187-4678","authenticated-orcid":false,"given":"Hongjian","family":"Ji","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Jiangsu Medical College, Yancheng City Therapeutic Drug Precision Testing Engineering Center, Yancheng 224005, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Affiliated Hospital 6 of Nantong University, Yancheng 224001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2513-4820","authenticated-orcid":false,"given":"Fengchao","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Affiliated Hospital 6 of Nantong University, Yancheng 224001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260805","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1186\/s40001-024-02081-2","article-title":"Utilizing surface-enhanced Raman spectroscopy for the adjunctive diagnosis of osteoporosis.","volume":"29","author":"Yang","year":"2024","journal-title":"Eur J Med Res"},{"key":"R2-20260805","doi-asserted-by":"crossref","first-page":"105029","DOI":"10.1016\/j.ijnurstu.2025.105029","article-title":"Comparative accuracy of osteoporosis risk assessment tools in postmenopausal women: a systematic review and network meta - analysis.","volume":"165","author":"Wang","year":"2025","journal-title":"Int J Nurs Stud"},{"key":"R3-20260805","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s13018-018-0865-3","article-title":"Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis.","volume":"13","author":"Wu","year":"2018","journal-title":"J Orthop Surg Res"},{"key":"R4-20260805","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1038\/550S15a","article-title":"Osteoporosis: staying strong.","volume":"550","author":"Brown","year":"2017","journal-title":"Nature"},{"key":"R5-20260805","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMcp2307353","article-title":"Postmenopausal Osteoporosis.","volume":"389","author":"Walker","year":"2023","journal-title":"N Engl J Med"},{"key":"R6-20260805","doi-asserted-by":"crossref","first-page":"e40594","DOI":"10.1097\/MD.0000000000040594","article-title":"Sequential treatment from bisphosphonate to denosumab improves lumbar spine bone mineral density in postmenopausal osteoporosis patients: a meta-analysis of randomized controlled trials.","volume":"103","author":"Jiang","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"R7-20260805","doi-asserted-by":"crossref","first-page":"e39642","DOI":"10.1097\/MD.0000000000039642","article-title":"Effect of denosumab, an anti-osteoporosis drug, on vascular calcification: a meta-analysis.","volume":"103","author":"Wang","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"R8-20260805","doi-asserted-by":"crossref","first-page":"1551542","DOI":"10.3389\/fimmu.2025.1551542","article-title":"From death to birth: how osteocyte death promotes osteoclast formation.","volume":"16","author":"Zhao","year":"2025","journal-title":"Front Immunol"},{"key":"R9-20260805","doi-asserted-by":"crossref","first-page":"e568","DOI":"10.1097\/RLU.0000000000005751","article-title":"68Ga PSMA PET\/CT and 18F FDG PET\/CT findings in osteonecrosis of the jaw induced by denosumab.","volume":"50","author":"Tosunoglu","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R10-20260805","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrd3705","article-title":"Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.","volume":"11","author":"Lacey","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"R11-20260805","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s00198-024-07118-0","article-title":"Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials.","volume":"35","author":"Kobayashi","year":"2024","journal-title":"Osteoporos Int"},{"key":"R12-20260805","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis.","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"R13-20260805","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R14-20260805","doi-asserted-by":"crossref","first-page":"1413515","DOI":"10.3389\/fphar.2024.1413515","article-title":"Additional effects of herbal medicine combined with bisphosphonates for primary osteoporosis: a systematic review and meta-analysis.","volume":"15","author":"Yoo","year":"2024","journal-title":"Front Pharmacol"},{"key":"R15-20260805","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomized FREEDOM trial and open-label extension.","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R16-20260805","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis.","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"R17-20260805","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/14712598.2024.2352587","article-title":"Randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of the denosumab Randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of the denosumab biosimilar MW031 in Chinese postmenopausal women with osteoporosis.","volume":"24","author":"Jiang","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"R18-20260805","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.","volume":"25","author":"Kendler","year":"2010","journal-title":"J Bone Miner Res"},{"key":"R19-20260805","doi-asserted-by":"crossref","first-page":"11801","DOI":"10.1038\/s41598-021-91248-6","article-title":"Denosumab versus romosozumab for postmenopausal osteoporosis treatment.","volume":"11","author":"Kobayakawa","year":"2021","journal-title":"Sci Rep"},{"key":"R20-20260805","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density.","volume":"354","author":"Mcclung","year":"2006","journal-title":"N Engl J Med"},{"key":"R21-20260805","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates.","volume":"101","author":"Miller","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"R22-20260805","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/jbmr.1479","article-title":"Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension.","volume":"27","author":"Papapoulos","year":"2012","journal-title":"J Bone Miner Res"},{"key":"R23-20260805","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","article-title":"Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial.","volume":"121","author":"Recknor","year":"2013","journal-title":"Obstet Gynecol"},{"key":"R24-20260805","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00198-024-07161-x","article-title":"Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis.","volume":"35","author":"Reginster","year":"2024","journal-title":"Osteoporos Int"},{"key":"R25-20260805","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00198-014-2964-2","article-title":"Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1- year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).","volume":"26","author":"Sugimoto","year":"2015","journal-title":"Osteoporos Int"},{"key":"R26-20260805","doi-asserted-by":"crossref","first-page":"116480","DOI":"10.1016\/j.bone.2022.116480","article-title":"Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12- month treatment with romosozumab as sequential therapy: the prospective VICTOR study.","volume":"162","author":"Kobayakawa","year":"2022","journal-title":"Bone"},{"key":"R27-20260805","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomized trial.","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"key":"R28-20260805","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41401-022-00954-y","article-title":"A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk.","volume":"44","author":"Zhang","year":"2023","journal-title":"Acta Pharmacol Sin"},{"key":"R29-20260805","first-page":"85","article-title":"Evaluation of the efficacy of denosumab in the treatment of postmenopausal osteoporosis with high fracture risk.","volume":"32","author":"Zhou","year":"2025","journal-title":"Chin J Clin Med"},{"key":"R30-20260805","doi-asserted-by":"crossref","first-page":"16532","DOI":"10.1038\/s41598-024-66836-x","article-title":"Effect of music therapy on anxiety and depression in breast cancer patients: systematic review and meta-analysis.","volume":"14","author":"Xu","year":"2024","journal-title":"Sci Rep"},{"key":"R31-20260805","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-022-06567-9","article-title":"The need to distinguish intervention thresholds and diagnostic thresholds in the management of osteoporosis.","volume":"34","author":"Kanis","year":"2023","journal-title":"Osteoporos Int"},{"key":"R32-20260805","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/jbmr\/zjae159","article-title":"Atypical fractures at non-classical sites associated with anti-resorptive therapy: a systematic review.","volume":"39","author":"Collins","year":"2024","journal-title":"J Bone Miner Res"},{"key":"R33-20260805","first-page":"299","article-title":"Low-molecular-weight estrogenic phytoprotein suppresses osteoporosis development through positive modulation of skeletal estrogen receptors.","volume":"42","author":"Kubi","year":"2024","journal-title":"Bioact Mater"},{"key":"R34-20260805","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1021\/acsami.2c19241","article-title":"Composite separable microneedles for transdermal delivery and controlled release of salmon calcitonin for osteoporosis therapy.","volume":"15","author":"Li","year":"2023","journal-title":"ACS Appl Mater Interfaces"},{"key":"R35-20260805","doi-asserted-by":"crossref","first-page":"e076898","DOI":"10.1136\/bmj-2023-076898","article-title":"Bisphosphonates.","volume":"386","author":"Billington","year":"2024","journal-title":"BMJ"},{"key":"R36-20260805","doi-asserted-by":"crossref","first-page":"e22542","DOI":"10.1097\/MD.0000000000022542","article-title":"Minodronate in the treatment of osteoporosis: a systematic review and meta-analysis.","volume":"99","author":"Liu","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"R37-20260805","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1007\/s00198-016-3607-6","article-title":"Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis.","volume":"27","author":"Beaudoin","year":"2016","journal-title":"Osteoporos Int"},{"key":"R38-20260805","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1742-1241.2011.02806.x","article-title":"Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis.","volume":"66","author":"Lin","year":"2012","journal-title":"Int J Clin Pract"},{"key":"R39-20260805","first-page":"2305","article-title":"Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis.","volume":"29","author":"Srivastava","year":"2021","journal-title":"Support Care Cancer"},{"key":"R40-20260805","doi-asserted-by":"crossref","first-page":"e2354734","DOI":"10.1001\/jamanetworkopen.2023.54734","article-title":"Denosumab and the risk of diabetes in patients treated for osteoporosis.","volume":"7","author":"Huang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R41-20260805","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7326\/M22-0684","article-title":"Effectiveness and safety of treatments to prevent fractures in people with low bone mass or primary osteoporosis: a living systematic review and network meta-analysis for the American College of Physicians.","volume":"176","author":"Ayers","year":"2023","journal-title":"Ann Intern Med"},{"key":"R42-20260805","doi-asserted-by":"crossref","first-page":"e39471","DOI":"10.1097\/MD.0000000000039471","article-title":"The role of short-chain fatty acids in the regulation of osteoporosis: new perspectives from gut microbiota to bone health: a review.","volume":"103","author":"Feng","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"R43-20260805","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1007\/s00198-016-3534-6","article-title":"Teriparatide for osteoporosis: importance of the full course.","volume":"27","author":"Lindsay","year":"2016","journal-title":"Osteoporos Int"},{"key":"R44-20260805","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1210\/jc.2011-3060","article-title":"Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis.","volume":"97","author":"Murad","year":"2012","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000047150","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T17:02:16Z","timestamp":1785949336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000047150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047150","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"2025-08-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}